Israeli pharmaceutical company Can-Fite BioPharma Ltd. has announced that it has raised NIS 26.5 million ($7.2 million) in its secondary offering on the Tel Aviv stock exchange. The company says that it will direct the funds towards a phase II/III clinical trial of its psoriasis treatment.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israel Invests Millions To Help AI Comprehend Hebrew, Arabic
September 21, 2023

Cybersecurity Startup Cato Raises $238M With $3B Valuation
September 21, 2023

Israel, UK Ink Deal For Greater Innovation Collaboration
September 21, 2023

ALS Drug Receives Patent In Israel, Europe, Japan
September 20, 2023
Facebook comments